Nurix Therapeutics (NRIX) Common Equity (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Common Equity data on file, last reported at $402.6 million in Q2 2026.

• On a quarterly basis, Common Equity fell 10.05% year-over-year to $402.6 million in Q2 2026; TTM through May 2026 was $402.6 million, a 10.05% decrease from a year earlier, with the FY2025 full-year figure at $538.7 million, up 2.23% from the prior year.
• Common Equity for Q2 2026 stood at $402.6 million, down from $480.9 million in the prior quarter.
• Over the last five years, Common Equity for NRIX reached as high as $538.7 million in Q4 2025 and fell as low as $168.7 million in Q1 2024.
• Historically, Common Equity has averaged $353.0 million across 5 years, with a median of $356.6 million in 2022.
• Across the five-year window, Common Equity slumped 38.42% in 2024 and jumped 184.99% in 2025, its largest moves.
• Year by year, Common Equity stood at $303.7 million in 2022, then slumped by 33.98% to $200.5 million in 2023, then jumped by 162.85% to $527.0 million in 2024, then increased by 2.23% to $538.7 million in 2025, then decreased by 25.27% to $402.6 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $402.6 million in Q2 2026, $480.9 million in Q1 2026, and $538.7 million in Q4 2025.